FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1969834418> ?p ?o ?g. }

• W1969834418 endingPage "793" @default.
• W1969834418 startingPage "786" @default.
• W1969834418 abstract "Recent bioterrorism raises the specter of reemergence of smallpox as a clinical entity. The mortality of variola major infection (‘typical smallpox’) was approximately 30% in past outbreaks. Programs for smallpox immunization for healthcare workers have been proposed. Atypical forms of smallpox presenting with flat or hemorrhagic skin lesions are most common in individuals with immune deficits with historic mortality approaching 100%. Smallpox vaccination, even after exposure, is highly effective. Smallpox vaccine contains a highly immunogenic live virus, vaccinia. Few data exist for the impact of variola or safety of vaccinia in immunocompromised hosts. Both disseminated infection by vaccinia and person‐to‐person spread after vaccination are uncommon. When it occurs, secondary vaccinia has usually affected individuals with pre‐existing skin conditions (atopic dermatitis or eczema) or with other underlying immune deficits. Historically, disseminated vaccinia infection was uncommon but often fatal even in the absence of the most severe form of disease, “progressive vaccinia”. Some responded to vaccinia immune globulin. Smallpox exposure would be likely to cause significant mortality among immunocompromised hosts. In the absence of documented smallpox exposures, immunocompromised hosts should not be vaccinated against smallpox. Planning for bioterrorist events must include consideration of uniquely susceptible hosts. Recent bioterrorism raises the specter of reemergence of smallpox as a clinical entity. The mortality of variola major infection (‘typical smallpox’) was approximately 30% in past outbreaks. Programs for smallpox immunization for healthcare workers have been proposed. Atypical forms of smallpox presenting with flat or hemorrhagic skin lesions are most common in individuals with immune deficits with historic mortality approaching 100%. Smallpox vaccination, even after exposure, is highly effective. Smallpox vaccine contains a highly immunogenic live virus, vaccinia. Few data exist for the impact of variola or safety of vaccinia in immunocompromised hosts. Both disseminated infection by vaccinia and person‐to‐person spread after vaccination are uncommon. When it occurs, secondary vaccinia has usually affected individuals with pre‐existing skin conditions (atopic dermatitis or eczema) or with other underlying immune deficits. Historically, disseminated vaccinia infection was uncommon but often fatal even in the absence of the most severe form of disease, “progressive vaccinia”. Some responded to vaccinia immune globulin. Smallpox exposure would be likely to cause significant mortality among immunocompromised hosts. In the absence of documented smallpox exposures, immunocompromised hosts should not be vaccinated against smallpox. Planning for bioterrorist events must include consideration of uniquely susceptible hosts." @default.
• W1969834418 created "2016-06-24" @default.
• W1969834418 creator A5019427610 @default.
• W1969834418 date "2003-07-01" @default.
• W1969834418 modified "2023-09-28" @default.
• W1969834418 title "Smallpox and Live-Virus Vaccination in Transplant Recipients" @default.
• W1969834418 cites W1515298765 @default.
• W1969834418 cites W1536010429 @default.
• W1969834418 cites W1653469804 @default.
• W1969834418 cites W1966161268 @default.
• W1969834418 cites W1966817834 @default.
• W1969834418 cites W1980492236 @default.
• W1969834418 cites W1985245015 @default.
• W1969834418 cites W2015609319 @default.
• W1969834418 cites W2023259585 @default.
• W1969834418 cites W2034226296 @default.
• W1969834418 cites W2042645790 @default.
• W1969834418 cites W2052108661 @default.
• W1969834418 cites W2057472952 @default.
• W1969834418 cites W2057527978 @default.
• W1969834418 cites W2060233039 @default.
• W1969834418 cites W2067594212 @default.
• W1969834418 cites W2076206356 @default.
• W1969834418 cites W2085361867 @default.
• W1969834418 cites W2089731941 @default.
• W1969834418 cites W2090828937 @default.
• W1969834418 cites W2099781636 @default.
• W1969834418 cites W2111960980 @default.
• W1969834418 cites W2118488619 @default.
• W1969834418 cites W2120905451 @default.
• W1969834418 cites W2122072514 @default.
• W1969834418 cites W2123778198 @default.
• W1969834418 cites W2135527980 @default.
• W1969834418 cites W2154665775 @default.
• W1969834418 cites W2172039135 @default.
• W1969834418 cites W2333089167 @default.
• W1969834418 cites W2341708842 @default.
• W1969834418 cites W235839431 @default.
• W1969834418 cites W2411432596 @default.
• W1969834418 cites W2415951718 @default.
• W1969834418 cites W4205156856 @default.
• W1969834418 cites W4213055573 @default.
• W1969834418 doi "https://doi.org/10.1034/j.1600-6143.2003.00145.x" @default.
• W1969834418 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/12814470" @default.
• W1969834418 hasPublicationYear "2003" @default.
• W1969834418 type Work @default.
• W1969834418 sameAs 1969834418 @default.
• W1969834418 citedByCount "15" @default.
• W1969834418 countsByYear W19698344182012 @default.
• W1969834418 countsByYear W19698344182013 @default.
• W1969834418 countsByYear W19698344182015 @default.
• W1969834418 countsByYear W19698344182017 @default.
• W1969834418 countsByYear W19698344182019 @default.
• W1969834418 countsByYear W19698344182020 @default.
• W1969834418 countsByYear W19698344182021 @default.
• W1969834418 crossrefType "journal-article" @default.
• W1969834418 hasAuthorship W1969834418A5019427610 @default.
• W1969834418 hasBestOaLocation W19698344181 @default.
• W1969834418 hasConcept C104317684 @default.
• W1969834418 hasConcept C116675565 @default.
• W1969834418 hasConcept C159047783 @default.
• W1969834418 hasConcept C203014093 @default.
• W1969834418 hasConcept C22070199 @default.
• W1969834418 hasConcept C2778417375 @default.
• W1969834418 hasConcept C2779094796 @default.
• W1969834418 hasConcept C2779272165 @default.
• W1969834418 hasConcept C2779827044 @default.
• W1969834418 hasConcept C2780801004 @default.
• W1969834418 hasConcept C2781356689 @default.
• W1969834418 hasConcept C2909788366 @default.
• W1969834418 hasConcept C40767141 @default.
• W1969834418 hasConcept C55493867 @default.
• W1969834418 hasConcept C71924100 @default.
• W1969834418 hasConcept C86803240 @default.
• W1969834418 hasConcept C8891405 @default.
• W1969834418 hasConceptScore W1969834418C104317684 @default.
• W1969834418 hasConceptScore W1969834418C116675565 @default.
• W1969834418 hasConceptScore W1969834418C159047783 @default.
• W1969834418 hasConceptScore W1969834418C203014093 @default.
• W1969834418 hasConceptScore W1969834418C22070199 @default.
• W1969834418 hasConceptScore W1969834418C2778417375 @default.
• W1969834418 hasConceptScore W1969834418C2779094796 @default.
• W1969834418 hasConceptScore W1969834418C2779272165 @default.
• W1969834418 hasConceptScore W1969834418C2779827044 @default.
• W1969834418 hasConceptScore W1969834418C2780801004 @default.
• W1969834418 hasConceptScore W1969834418C2781356689 @default.
• W1969834418 hasConceptScore W1969834418C2909788366 @default.
• W1969834418 hasConceptScore W1969834418C40767141 @default.
• W1969834418 hasConceptScore W1969834418C55493867 @default.
• W1969834418 hasConceptScore W1969834418C71924100 @default.
• W1969834418 hasConceptScore W1969834418C86803240 @default.
• W1969834418 hasConceptScore W1969834418C8891405 @default.
• W1969834418 hasIssue "7" @default.
• W1969834418 hasLocation W19698344181 @default.
• W1969834418 hasLocation W19698344182 @default.
• W1969834418 hasOpenAccess W1969834418 @default.
• W1969834418 hasPrimaryLocation W19698344181 @default.
• W1969834418 hasRelatedWork W1984263551 @default.

• next